Blood Lactate: A New Biomarker for Prognosis in Neuromuscular Disease
A new study published in *Annals of Neurology* identifies blood lactate as a significant prognostic biomarker for patients with amyotrophic lateral sclerosis (ALS). In a retrospective analysis of two independent cohorts, researchers found that lower blood lactate levels were independently associated with shorter survival times and greater weight loss. The findings suggest that lactate, a key energy substrate, may serve as a valuable indicator of nutritional status and disease progression in this patient population.
Why it might matter to you: For anesthesiologists managing patients with neuromuscular diseases, this research highlights a potential metabolic marker for preoperative risk stratification. Understanding a patient’s metabolic reserve, as indicated by lactate levels, could inform decisions regarding anesthetic agent selection, perioperative nutritional support, and postoperative monitoring strategies in high-risk surgical cases.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
